As
filed with the Securities and Exchange Commission on November 3,
2006
Registration
No. 333-
U.S. SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form S-3
REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933
MOOG
INC.
(Exact
name of registrant as specified in its charter)
New
York
|
|
16-0757636
|
(State
of Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
East
Aurora, New York 14052-0018
(716) 652-2000
(Address,
including zip code, and telephone number, including area code, of registrant’s
principal executive offices)
Robert
R. Banta, Executive Vice President and
Chief
Financial Officer
East
Aurora, New York 14052-0018
(716) 652-2000
(Name,
address, including zip code, and telephone number, including area code, of
agent
for service)
Copy
to:
John
B. Drenning, Esq.
Robert
J. Olivieri, Esq.
Hodgson
Russ LLP
One
M&T Plaza, Suite 2000
Buffalo,
New York 14203
(716) 856-4000
Approximate
date of commencement of proposed sale to the public:
From
time to time after this Registration Statement becomes effective.
If
the
only securities being registered on this Form are being offered pursuant to
dividend or interest reinvestment plans, please check the following
box. o
If
any of
the securities being registered on this Form are to be offered on a delayed
or
continuous basis pursuant to Rule 415 under the Securities Act of 1933,
other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box. þ
If
this
Form is filed to register additional securities for an offering pursuant to
Rule 462(b) under the Securities Act, please check the following box and
list the Securities Act registration number of the earlier effective
registration statement for the same
offering. o
If
this
Form is a post-effective amendment filed pursuant to Rule 462(c) under the
Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same
offering. o
If
this
Form is a registration statement pursuant to the General Instruction I.D.
or a post-effective amendment thereto that shall become effective upon filing
with the Commission pursuant to Rule 462(e) under the Securities Act, check
the following box. þ
If
this
Form is a post-effective amendment to a registration statement filed pursuant
to
General Instruction I.D. filed to register additional securities or
additional classes of securities pursuant to Rule 413(b) under the
Securities Act, check the following box. o
CALCULATION
OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
Title
of Each Class
|
|
|
|
|
|
Proposed
Maximum
|
|
|
Proposed
Maximum
|
|
|
|
of
Securities to be
|
|
|
Amount
to be
|
|
|
Offering
Price Per
|
|
|
Aggregate
Offering
|
|
|
Amount
of
|
Registered
|
|
|
Registered
|
|
|
Share(1)
|
|
|
Price
|
|
|
Registration
Fee
|
|
|
|
|
|
|
|
|
|
|
|
|
|
C
Class A Common Stock, $1.00 par value per share
|
|
|
445,725
shares
|
|
|
$37.47
|
|
|
$16,701,316
|
|
|
$1,788
|
(1)
|
Estimated
solely for the purpose of calculating the registration fee pursuant
to In
accordance with Rules 457(c) and 457(r) under
the Securities Act of 1933, as amended, based upon the
average of the high and low prices of the Registrant’s common shares
reported on the New York Stock Exchange on October 30,
2006.
|
|
|
(2)
|
A
filing fee in the amount of $1,756 previously paid by the registrant
with
respect to Registration No. 333-138149 filed on October 23, 2006
and
withdrawn on October 31, 2006 is being used to offset this
fee.
|
PROSPECTUS
MOOG
INC.
445,725
SHARES
CLASS A
COMMON STOCK
This
prospectus relates to the resale from time to time of up to 445,725 shares
of
our Class A common stock by the selling shareholder described in the
section entitled “Selling Shareholder” beginning on page 9 of this prospectus.
The shares were issued to the selling shareholder in connection with our
acquisition of McKinley Medical Corporation in a merger transaction.
The
selling shareholder may offer and sell any of the shares of the Class A
common stock from time to time at fixed prices, at market prices or at
negotiated prices, and may engage a broker, dealer or underwriter to sell the
shares. For additional information on the possible methods of sale that may
be
used by the selling shareholder, you should refer to the section entitled “Plan
of Distribution” on page 11 of this prospectus. We will not receive any proceeds
from the sale of the shares of Class A common stock by the selling shareholder.
Our
Class A common stock is listed on the New York Stock Exchange under the
trading symbol “MOG.A.” On November 1, 2006 the last reported sale price for our
Class A common stock was $36.30 per share.
You
should consider carefully the risks that we have described in “Risk Factors”
beginning on page 5 of this prospectus before deciding whether to invest in
our
stock.
Neither
the Securities and Exchange Commission nor any state securities commission
has
approved or disapproved of these securities or passed upon the adequacy or
accuracy of this prospectus. Any representation to the contrary is a criminal
offense.
The
date
of this prospectus is November 3, 2006.
TABLE
OF CONTENTS
Page
No.
|
|
ABOUT
THIS PROSPECTUS
|
i
|
AVAILABLE
INFORMATION
|
ii
|
SUMMARY
|
1
|
RISK
FACTORS
|
5
|
DISCLOSURE
REGARDING FORWARD-LOOKING STATEMENTS
|
6
|
USE
OF PROCEEDS
|
8
|
DESCRIPTION
OF CAPITAL STOCK
|
8
|
SELLING
SHAREHOLDER
|
10
|
PLAN
OF DISTRIBUTION
|
11
|
LEGAL
MATTERS
|
12
|
EXPERTS
|
12
|
This
prospectus is part of a registration statement on Form S-3 that we filed
with the Securities and Exchange Commission, or the SEC. Pursuant to this
prospectus, the selling shareholder named on page 10 may sell up to a total
of 445,725 shares of our Class A common stock. This prospectus and the documents
incorporated by reference herein include important information about us, the
Class A common stock being offered and other information you should know before
investing. You should read this prospectus together with the additional
information about us described in the sections below entitled “Available
Information” and “Incorporation of Certain Information by Reference.” You should
rely only on information contained in, or incorporated by reference into, this
prospectus. We have not authorized anyone to provide you with information
different from that contained in, or incorporated by reference into, this
prospectus. The information contained in this prospectus is accurate only as
of
the date on the front cover of the prospectus and information we have
incorporated by reference in this prospectus is accurate only as of the date
of
the document incorporated by reference. You should not assume that the
information contained in, or incorporated by reference into, this prospectus
is
accurate as of any other date.
References
to “Moog” refer to Moog Inc. Unless the context otherwise requires, references
to “we,” “us” or “our” refer collectively to Moog Inc. and its
subsidiaries.
We
are a
public company and are required to file annual, quarterly and current reports,
proxy statements and other information with the SEC pursuant to the Securities
Exchange Act of 1934, as amended (hereinafter referred to as the “Exchange
Act”). You may read and copy any document we file at the SEC’s Public Reference
Room at 100 F Street, N.E., Washington, D.C. 20549. You can request copies
of these documents by writing to the SEC and paying a fee for the copying cost.
Please call the SEC at 1-800-SEC-0330 for more information about the operation
of the public reference room and its copy charges. Our SEC filings are also
available to the public on the SEC’s web site at “http:/ /www.sec.gov.” In
addition, our stock is listed for trading on the New York Stock Exchange. You
can read and copy reports and other information concerning us at the offices
of
the National Association of Securities Dealers, Inc. located at 1735 K
Street, Washington, D.C. 20006.
The
SEC
allows us to “incorporate by reference” in this prospectus the information in
documents filed with it. This means that we can disclose important information
to you by referring you to these documents. The information incorporated by
reference is considered to be a part of this prospectus, and information in
documents that we file later with the SEC will automatically update and
supersede information contained in documents filed earlier with the SEC or
contained in this prospectus or any prospectus supplement.
We
incorporate by reference in this prospectus the documents listed below and
any
future filings that we may make with the SEC under Sections 13(a), 13(c),
14 or 15(d) of the Securities Exchange Act of 1934, or the Exchange Act, prior
to the termination of this offering. These additional documents include periodic
reports, such as annual reports on Form 10-K, quarterly reports on
Form 10-Q and current reports on Form 8-K (other than information
furnished under Items 2.02 and 7.01, which is deemed not to be incorporated
by reference in this prospectus). You should review these filings as they may
disclose a change in our business, prospects, financial condition or other
affairs after the date of this prospectus.
This
prospectus incorporates by reference the documents listed below that we have
filed with the SEC but have not been included or delivered with this document:
|
|
|
|
•
|
Our
Annual Report on Form 10-K for the year ended September 24,
2005;
|
|
|
|
|
•
|
Our
Quarterly Reports on Form 10-Q for the quarters ended
December 31, 2005, April 1, 2006 and July 1, 2006;
|
|
|
|
|
•
|
Our
Current Reports on Form 8-K filed November 23, 2005,
December 2, 2005, December 28, 2005, January 30, 2006,
February 13, 2006, February 15, 2006, February 21, 2006, April 11,
2006, August 28, 2006 and October 27, 2006; and
|
|
|
|
|
•
|
The
description of our common stock contained in our Registration Statement
on
Form S-3 filed on November 9,
2001.
|
You
may
request a copy of these documents, at no cost to you, by writing or telephoning
us at:
Moog
Inc.
Seneca
St. at Jamison Rd.
Corporate
Offices
East
Aurora, NY 14052
Attention:
Investor Relations
(716) 652-2000
Any
statement made in this prospectus concerning the contents of any contract,
agreement or other document is only a summary of the actual document. You may
obtain a copy of any document summarized in this prospectus or any prospectus
supplement at no cost by writing to or telephoning us at the address and
telephone number given above. Each statement regarding a contract, agreement
or
other document is qualified in its entirety by reference to the actual
document.
This
summary highlights only some of the information included or incorporated by
reference in this prospectus. You should carefully read this prospectus together
with the additional information about us described in the sections entitled
“Available Information” before purchasing our Class A common
stock.
Overview
We
are a
leading worldwide designer and manufacturer of high performance, precision
motion and fluid controls and control systems for a broad range of applications
in aerospace, defense and industrial markets. Our products and systems include
military and commercial aircraft flight controls, satellite positioning
controls, controls for steering tactical and strategic missiles, thrust vector
controls for space launch vehicles and controls for positioning gun barrels
and
automatic ammunition loading for military combat vehicles. Our products are
also
used in a wide variety of industrial applications, including injection molding
machines for the plastics markets, metal forming, power generating turbines,
simulators used to train pilots and certain medical applications.
Our
customers fall into three groups, Original Equipment Manufacturers, or OEMs,
that are customers of our aerospace and defense markets, OEM customers of our
industrial business and aftermarket customers in all of our markets. Aerospace
and defense OEM customers collectively represented 46% of our fiscal 2005 sales.
The majority of these sales are to a small number of large companies. Due to
the
long-term nature of many of the programs, many of our relationships with
aerospace and defense OEM customers are based on long-term agreements. Our
OEM
sales of industrial controls, which represented 33% of our fiscal 2005 sales,
are to a wide diversity of customers around the world and are normally based
on
lead times of 90 days or less. We also provide aftermarket support,
consisting of spare and replacement parts and repair and overhaul services,
for
all of our product applications. Our major aftermarket customers are the
U.S. Government and the commercial airlines. In fiscal 2005, aftermarket
sales accounted for 21% of total sales. Sales arising from U.S. Government
prime or subcontracts, including military sales to Boeing and Lockheed Martin,
were approximately 34% of our fiscal 2005 sales.
We
have
five reportable segments: (1) Aircraft Controls, (2) Space and Defense
Controls, (3) Industrial Controls, (4) Components and (5) Medical
Devices.
Our
Aircraft Controls Segment
Within
Aircraft Controls, we design, manufacture and integrate primary and secondary
flight controls for military and commercial aircraft, and provide aftermarket
support. Our systems control large commercial transports, supersonic fighters,
multi-role military aircraft, business jets and rotorcraft.
We
are
well positioned on both development and production programs. Typically,
development programs require concentrated periods of research and development
by
our engineering teams and involve design, development, testing and integration.
We are currently working on several large development programs including the
F-35 Joint Strike Fighter, India’s Light Combat Aircraft, Boeing’s 787
Dreamliner, Airbus’ A400M and two unmanned aerial vehicles, the X-45 and X-47.
The F-35 is the largest of these programs. The 787 and the A400M programs began
design and development in 2004. Production programs are generally long-term
manufacturing efforts that extend for as long as the aircraft builder receives
new orders. Our large military production programs include the F/A-18 E/F Super
Hornet, F-15 Eagle and the V-22 Osprey. Our large commercial production programs
include the full line of Boeing 7-series aircraft.
Our
Space and Defense Controls Segment
Our
Space
and Defense Controls segment provides controls for satellites and space
vehicles, launch vehicles, tactical and strategic missiles, missile defense
and
defense controls. For the commercial and military satellite markets, we design,
manufacture and integrate chemical and electric propulsion systems and space
flight motion controls. Launch vehicles and missiles use our steering and
propulsion controls, and the Space Station uses our couplings, valves and
actuators. We design and build steering and propulsion controls for tactical
and
strategic missile programs, including VT-1, Hellfire and TOW. We supply valves
on the final stage kill vehicle used in the U.S. National Missile Defense
development initiative. We design and manufacture systems to position gun
barrels and automatically load ammunition on military vehicles.
Our
Industrial Controls Segment
Industrial
Controls is a diverse segment, serving customers around the world and in many
markets. Six major markets — plastics making machinery, power generating
turbines, metal forming, heavy industry, test and simulation — generate
over half of our total sales in this segment. For the plastics making machinery
market, we design, manufacture and integrate systems for all axes of injection
and blow molding machines using leading edge technology, both hydraulic and
electric. In the power generation turbine market, we design, manufacture and
integrate complete control assemblies for fuel, steam and variable geometry
control applications that include wind turbines. Metal forming markets use
our
designed and manufactured systems that provide precise control of position,
velocity, force, pressure, acceleration and other critical parameters. Heavy
industry uses our high precision electrical and hydraulic servovalves for steel
and aluminum mill equipment. For the test markets, we supply controls for
automotive testing, structural testing and fatigue testing. Our hydraulic and
electromechanical motion simulation bases are used for the flight simulation
and
training markets. Other markets include material handling, auto racing, carpet
tufting, paper mills and lumber mills.
Our
Components Segment
Many
of
the same markets, including military and commercial aerospace, defense controls
and industrial applications, that drive sales as described in the previous
three
segments affect Components. In addition, Components serves two medical equipment
markets.
This
segment’s three largest product categories, slip rings, fiber optic rotary
joints and motors, serve broad markets. Slip rings and fiber optic rotary joints
use sliding contacts and optical technology to allow unimpeded rotation while
delivering power and data across a rotating interface. They come in a range
of
sizes that allow them to be used in many applications that include diagnostic
imaging, particularly CT scan medical equipment featuring high-speed data
communications, de-icing and data transfer for rotorcraft, forward-looking
infrared camera installations, radar pedestals, material handling, surveillance
cameras, packaging and robotics. Our motors are used in equally broad-based
markets, many of which are the same as for slip rings. For the medical pump
and
blower market, and particularly sleep apnea equipment, Components designs and
manufactures a series of miniature brushless motors that provide extremely
low
noise and reliable long life operation. Industrial markets use our motors for
material handling, fuel cells and electric pumps. Military applications use
our
motors for gimbals, missiles and radar pedestals. Components has several other
product lines including electromechanical actuators for military, aerospace
and
commercial applications, fiber optic modems that provide electrical-to-optical
conversion of communication and data signals, avionic instrumentation, optical
switches and resolvers.
Our
Medical Devices Segment
Medical
Devices is our newest segment, formed as a result of the acquisitions of Curlin
Medical and McKinley Medical in 2006. These product lines expand our
participation in our target medical markets beyond the supply of component
parts
and assemblies that have already been an integral part of our Components
segment. Curlin products include infusion pumps that provide controlled delivery
of therapeutic drugs to the patient, either in a hospital or in an outpatient
setting. The technology employed in infusion pumps today includes microprocessor
controls and sophisticated software. McKinley products include disposable pumps
and accessories used principally to administer therapeutic drugs for
chemotherapy and antibiotic applications, and post-operative pain medication
for
pain management. We believe that our extensive background in electronic control
of fluid-flow metering devices combined with the reputation of these products
in
the medical devices market will result in further strategic growth of this
new
segment.
The
Offering
Securities
offered by the selling shareholder
|
|
Up
to 445,725 shares of our Class A common stock.
|
|
|
|
Use
of proceeds
|
|
We
will not receive any proceeds from the sale of the Class A common
stock
offered by this prospectus.
|
|
|
|
New
York Stock Exchange Symbol
|
|
MOG.A
|
Investing
in our Class A common stock involves a high degree of risk. Before you
invest in our Class A common stock, you should understand and carefully
consider the risks described below and the risk factors relating to our industry
and business described in our Annual Report on Form 10-K for the year ended
September 24, 2005, as well as all of the other information contained in
this prospectus, the applicable prospectus supplement and the information
incorporated by reference, including our financial statements and the related
notes. Any of these risks could materially adversely affect our business,
financial condition, results of operations and the trading price of our
Class A common stock, and you may lose all or part of your
investment.
The
voting rights of the Class A common stock are limited.
The
voting rights of the holders of Class A common stock are limited by our
certificate of incorporation. Holders of Class A common stock are entitled
to elect at least 25% of the board of directors, rounded up to the nearest
whole
number, so long as the outstanding shares of Class A common stock are at
least 10% of the aggregate number of outstanding shares of Class A common
stock and Class B common stock combined. Currently, the holders of
Class A common stock are entitled, as a class, to elect three directors.
The holders of the Class B common stock are entitled, as a class, to elect
the remaining eight directors. On all other matters except as is required by
law, the Class A and Class B common stock vote together as a single
class with each share of Class A common stock entitled to a one-tenth vote
per share and each share of Class B common stock entitled to one vote per
share.
Our
officers and directors and shareholders affiliated with them control the vote
of
a significant percentage of our voting stock and as a result exert influence
over us, and may have interests that conflict with those of other shareholders,
including purchasers of Class A common stock.
As
of
September 30, 2006, approximately 74.7% of the Class B common stock and
approximately 5.7% of the Class A common stock was held in the aggregate by
the Moog Inc. Savings and Stock Ownership Plan Trust, the Moog Inc. Retirement
Plan Trust, relatives of the late Jane B. Moog subject to The Moog Family
Agreement as to Voting and our officers and directors. These shareholders as
a
group possess the voting power to elect a majority of the board of directors
and
to effectively control our business policies and affairs, and may have interests
that conflict with those of other shareholders, including purchasers of our
Class A common stock.
New
York law and our certificate of incorporation and by-laws contain provisions
that could delay and discourage takeover attempts that shareholders may consider
favorable.
Certain
provisions of our certificate of incorporation and by-laws and applicable
provisions of New York corporate law may make it more difficult for or prevent
a
third party from acquiring control of us or changing our board of directors
and
management. These provisions include:
|
|
|
|
•
|
the
limited voting rights of the Class A common stock and the fact that,
as of September 30, 2006, approximately 5.7% of the Class A and
approximately 74.7% of the Class B common stock, representing
approximately 43.6% of the voting power of our outstanding common
stock,
is owned or controlled by our affiliates;
|
|
|
|
|
•
|
our
ability under our certificate of incorporation to issue additional
shares
of Class B common stock and shares of “blank check” preferred stock
without action of the shareholders;
|
|
|
|
|
•
|
provisions
of our certificate of incorporation and by-laws which create a staggered
board of directors with each director elected for a three-year
term; and
|
|
|
|
|
•
|
provisions
of New York corporate law which impose limitations on persons proposing
to
acquire us in a transaction not approved by our board of
directors.
|
Any
delay
or prevention of a change of control transaction or changes in our board of
directors or management could deter potential acquirors or prevent the
completion of a transaction in which our stockholders could receive a
substantial premium over the then-current market price for their shares.
Possible
volatility in the price of our common stock could negatively affect us and
our
shareholders.
The
trading price of our Class A common stock may be volatile in response to a
number of factors, many of which are beyond our control, including actual or
anticipated variations in quarterly financial results, changes in financial
estimates by securities analysts and announcements by our competitors of
significant acquisitions, strategic partnerships, joint ventures or capital
commitments. In addition, our financial results may be below the expectations
of
securities analysts and investors. If this were to occur, the market price
of
our Class A common stock could decrease, perhaps significantly.
Additionally, our Class A common stock has historically had low trading
volumes. The limited liquidity for holders of our Class A common stock may
add to the volatility of the trading price of our common stock. For example,
from September 30, 2003 to September 30, 2006, the sales prices of our
Class A common stock have ranged from $17.42 per share to
$40.65 per share. These effects could materially adversely affect the
trading market and prices for our Class A common stock, as well as our
ability to issue additional securities or to secure additional financing in
the
future.
In
addition, the U.S. securities markets have experienced significant price
and volume fluctuations. These fluctuations often have been unrelated to the
operating performance of companies in these markets. Broad market and industry
factors may negatively affect the price of our Class A common stock,
regardless of our operating performance.
DISCLOSURE
REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus, including the documents we incorporate by reference, contains
forward-looking statements within the meaning of Section 27A of the
Securities Act and Section 21E of the Exchange Act. These forward-looking
statements are not historical facts, but only predictions and generally can
be
identified by the use of statements that include terms such as “believe,”
“expect,” “anticipate,” “estimate,” “could,” “plan,” “intend,” “may,” “project,”
“predict,” “will” and terms and phrases of similar import. Although we believe
the assumptions upon which these forward-looking statements are based are
reasonable, any of these assumptions could prove to be inaccurate, and the
forward-looking statements based on these assumptions could be incorrect. While
we have made these forward-looking statements in good faith and they reflect
our
current judgment regarding such matters, actual results could vary materially
from the forward-looking statements. Accordingly, these forward-looking
statements are qualified in their entirety by reference to the factors described
in “Risk Factors” as well as to other factors described below and the
information in the documents incorporated by reference herein. The
forward-looking statements included in this prospectus are made only as of
their
respective dates, and we undertake no obligation to publicly update these
forward-looking statements to reflect new information, future events or
otherwise.
Important
factors affecting forward-looking statements in this prospectus include, but
are
not limited to, the following:
|
|
|
|
•
|
fluctuations
in general business cycles for commercial aircraft, military aircraft,
space and defense products and industrial capital
goods;
|
|
|
|
|
•
|
our
dependence on government contracts, which may not be fully funded
or may
be terminated;
|
|
|
|
|
•
|
our
significant indebtedness, which could limit our cash flow for operations
and flexibility;
|
|
|
|
|
•
|
the
possibility that our subcontractors may fail to perform their contractual
obligations, which may adversely affect our contract performance
and our
ability to obtain future business;
|
|
|
|
|
•
|
the
potential for cost overruns on fixed-price contracts and the risk
that
actual results may differ from estimates used, including those used
in
accounting for long-term contracts;
|
|
•
|
the
potential for substantial fines and penalties or suspension or debarment
from future contracts in the event we do not comply with regulations
relating to defense industry contracting;
|
|
|
|
|
•
|
the
potential that the demand for our products may be reduced if we are
unable
to adapt to technological change;
|
|
|
|
|
•
|
the
possibility that our new products and research and development efforts
may
not be successful, which would result in a reduction in our sales
and
profits;
|
|
|
|
|
•
|
our
dependence on certain major customers, such as The Boeing Company
and
Lockheed Martin, for a significant percentage of our
sales;
|
|
|
|
|
•
|
intense
competition in our business which may require us to lower prices
or offer
more favorable terms of sale;
|
|
|
|
|
•
|
higher
pension costs and increased cash funding requirements, which could
occur
in future years if future actual plan results differ from assumptions
used
for our defined benefit plans, including returns on plan assets and
discount rates;
|
|
|
|
|
•
|
a
write-off of all or part of our goodwill or other intangible assets,
which
could adversely affect our operating results and net worth and cause
us to
violate covenants in our bank agreements;
|
|
|
|
|
•
|
our
ability to successfully identify and consummate acquisitions and
integrate
the acquired businesses;
|
|
|
|
|
•
|
our
exposure to successor liability relating to actions by an acquired
company
and its management before the acquisition;
|
|
|
|
|
•
|
the
possibility that the due diligence we conduct in connection with
an
acquisition, and any contractual guarantees or indemnities that we
receive
from the sellers of acquired companies, may not be sufficient to
protect
us from, or compensate us for, actual liabilities whereby a material
liability could adversely affect our reputation and results of operations
and reduce the benefits of the acquisition;
|
|
|
|
|
•
|
our
dependence on our management team and key personnel;
|
|
|
|
|
•
|
the
possibility that future terror attacks, war or other civil disturbances
could negatively impact our business;
|
|
|
|
|
•
|
our
operations in foreign countries could expose us to political risks
and
adverse changes in local, legal, tax and regulatory
schemes;
|
|
|
|
|
•
|
the
possibility that government regulation could inhibit our ability
to sell
our products outside the United States;
|
|
|
|
|
•
|
the
possibility of a catastrophic loss of one or more of our manufacturing
facilities;
|
|
|
|
|
•
|
the
impact of product liability claims related to our products used in
applications where failure can result in significant property damage,
injury or death and in damage to our reputation;
|
|
|
|
|
•
|
foreign
currency fluctuations in those countries in which we do business
and other
risks associated with international operations; and
|
|
|
|
|
•
|
the
cost of compliance with environmental
laws.
|
We
will
not receive any proceeds from the sale of the shares of our Class A common
stock
by the selling shareholder.
Our
authorized capital stock consists of 50,000,000 shares of Class A
common stock, par value $1.00 per share, 10,000,000 shares of
Class B common stock, par value $1.00 per share and
10,000,000 shares of preferred stock, par value $1.00 per share. As of
September 30, 2006, we had outstanding 38,086,286 shares of Class A
common stock and 4,209,585 shares of Class B common stock. As of
September 30, 2006, we had 1,782,714 shares of Class A common stock
issuable upon exercise of outstanding stock options under our stock option
plans
at a weighted average price of $18.20 per share, 548,453 shares of
Class A common stock reserved and available for future issuance under our
stock option plans, and 4,209,585 shares of Class A common stock
issuable upon conversion of our shares of Class B common stock then
outstanding. As of September 30, 2006, no shares of preferred stock were
outstanding. The following description of our capital stock is a summary only
and is derived from our certificate of incorporation, which is incorporated
by
reference into this prospectus.
Common
Stock
The
Class A common stock and Class B common stock share equally in our
earnings and are identical except with respect to rights on voting, dividends
and share distributions and convertibility.
Voting
Rights.
The
Class A common stock and Class B common stock vote as a single class
on all matters except election of directors and except as required by law.
Holders of Class A common stock are entitled to elect at least 25% of the
board of directors, rounded up to the nearest whole number, so long as the
outstanding shares of Class A common stock are at least 10% of the
aggregate number of outstanding shares of Class A common stock and
Class B common stock combined. The holders of Class B common stock
elect the remaining directors. Currently, the holders of Class A common
stock are entitled, as a class, to elect three directors. The holders of the
Class B common stock are entitled, as a class, to elect our remaining eight
directors. On all other matters, the holders of Class A common stock are
entitled to one-tenth of a vote. Each share of Class B common stock is
entitled to one vote. If the outstanding shares of Class A common stock
become less than 10% of the aggregate number of outstanding shares of both
classes combined, the holders of Class A common stock would not have the
right to elect 25% of the board of directors. Directors would then be elected
by
all shareholders voting as a single class, with holders of Class A common
stock having a one-tenth vote per share and holders of Class B common stock
having one vote per share.
Dividends
and Share Distributions.
Dividends may be paid on Class A common stock without paying a dividend on
Class B common stock. No dividend may be paid on Class B common stock
unless at least an equal dividend is paid on Class A common stock. Payment
of dividends is limited by our bank credit facility. Share distributions in
shares of Class A common stock or Class B common stock may be paid
only as follows. Shares of Class A common stock are paid to holders of
shares of Class A common stock or, if there is no Class A common stock
outstanding, to holders of Class B common stock. Shares of Class A
common stock are paid to holders of Class A common stock and shares of
Class B common stock are paid to holders of Class B common stock. The
same number of shares must be paid in respect of each outstanding share of
Class A common stock and Class B common stock.
We
may
not combine or subdivide shares of either class of common stock without at
the
same time proportionally subdividing or combing shares of the other class.
Conversion.
Each
share of Class B common stock is convertible at the option of the holder at
any time into Class A common stock on a one-for-one basis.
Preferred
Stock
Our
board
of directors is authorized, without shareholder action, to issue shares of
preferred stock in one or more series. The board has the discretion to determine
the rights, preferences and limitations of each series, including voting rights,
dividend rights, conversion rights, redemption privileges and liquidation
preferences. Satisfaction of any dividend preference of outstanding shares
of
preferred stock would reduce the amount of funds available for the payment
of
dividends on shares of common stock. In some circumstances, the issuance of
shares of preferred stock may render more difficult or tend to discourage a
merger, tender offer or proxy contest, the assumption of control by a holder
of
a large block of our securities or the removal of incumbent management. We
have
no current intention to issue any shares of preferred stock.
Transfer
Agent and Registrar
The
transfer agent and registrar for our Class A common stock is:
Mellon
Investor Services
111
Founders Plaza
East
Hartford, Connecticut 06108
(860)
282-3509
We
have
issued 445,725 shares of our Class A common stock to the selling shareholder
named below in connection with our acquisition by merger of McKinley Medical
Corporation. We have filed this prospectus in order to permit the selling
shareholder to resell to the public these shares of Class A common stock issued
in connection with that transaction.
The
following table, to our knowledge, sets forth information regarding the
beneficial ownership of our Class A common stock by the selling shareholder
as
of September 30, 2006 and the number of shares being offered hereby by the
selling shareholder. For purposes of the following description, the term
“selling shareholder” includes pledgees, donees, permitted transferees or other
permitted successors-in-interest selling shares received after the date of
this
prospectus from the selling shareholder. The information is based on information
provided by or on behalf of the selling shareholder. Beneficial ownership is
determined in accordance with the rules of the SEC, and includes voting or
investment power with respect to shares, as well as any shares as to which
the
selling shareholder has the right to acquire beneficial ownership within sixty
(60) days after September 30, 2006 through the exercise or conversion of
any stock options, warrants, convertible debt or otherwise. Unless otherwise
indicated below, the selling stockholder has sole voting and investment power
with respect to its shares of common stock. The inclusion of any shares in
this
table does not constitute an admission of beneficial ownership for the selling
stockholder. We will not receive any of the proceeds from the sale of our common
stock by the selling stockholder.
|
|
Shares
Beneficially Owned
Prior
to Offering
|
|
Shares
Being
|
|
Shares
Beneficially Owned
After
Offering(1)
|
|
Selling
Shareholder
|
|
Number
|
|
Percent(2)
|
|
Offered
|
|
Number
|
|
Percent(2)
|
|
McKinley
Medical, LLC (3)
252
Clayton Street, 4th
Floor
Denver,
Colorado 80206
|
|
|
445,725
|
|
|
1.2
|
%
|
|
445,725
|
|
|
0
|
|
|
0
|
%
|
(1)
We do not know when or in what amounts the selling shareholder may offer for
sale the shares of Class A common stock pursuant to this offering. The selling
shareholder may choose not to sell any of the shares offered by this prospectus.
Because the selling shareholder may offer all or some of the shares of common
stock pursuant to this offering, and because there are currently no agreements,
arrangements or undertakings with respect to the sale of any of the shares
of
Class A common stock, we cannot estimate the number of shares of Class A common
stock that the selling shareholder will hold after completion of the offering.
For purposes of this table, however, we have assumed that the selling
shareholder will have sold all of the shares covered by this prospectus upon
the
completion of the offering.
(2)
Percentages are based on 38,086,286 shares of Class A common stock that were
issued and outstanding as of September 30, 2006.
(3)
The principal beneficial owners of McKinley Medical, LLC are Pat Broe (78.43%),
a trust for the benefit of Mr. Broe’s children (11.47%), Randy Hoffman (10%).
The address for each of Messrs. Broe and Hoffman and the trust is 252 Clayton
Street, 4th
Floor,
Denver, Colorado 80206.
The
selling shareholder may, from time to time, sell any or all of their shares
of
Class A common stock on any stock exchange, market or trading facility on which
the shares are traded or in private transactions. These sales may be at fixed
or
negotiated prices. The selling shareholder may use any one or more of the
following methods when selling shares:
|
• |
ordinary
brokerage transactions and transactions in which the broker-dealer
solicits purchasers;
|
|
• |
block
trades in which the broker-dealer will attempt to sell the shares
as agent
but may position and resell a portion of the block as principal to
facilitate the transaction;
|
|
• |
purchases
by a broker-dealer as principal and resale by the broker-dealer for
its
account;
|
|
• |
an
exchange distribution in accordance with the rules of the applicable
exchange;
|
|
• |
privately
negotiated transactions;
|
|
• |
broker-dealers
may agree with the selling shareholder to sell a specified number
of such
shares at a stipulated price per
share;
|
|
• |
a
combination of any such methods of sale;
and
|
|
• |
any
other method permitted pursuant to applicable
law.
|
The
selling shareholder may also sell shares under Rule 144 under the
Securities Act, if available, rather than under this prospectus.
The
selling shareholder may also engage in short sales against the box, puts and
calls and other transactions in our securities or derivatives of our securities
and may sell or deliver shares in connection with these trades.
Broker-dealers
engaged by the selling shareholder may arrange for other brokers-dealers to
participate in sales. Broker-dealers may receive commissions or discounts from
the selling shareholder (or, if any broker-dealer acts as agent for the
purchaser of shares, from the purchaser) in amounts to be negotiated. The
selling shareholder do not expect these commissions and discounts to exceed
what
is customary in the types of transactions involved. Any profits on the resale
of
shares of common stock by a broker-dealer acting as principal might be deemed
to
be underwriting discounts or commissions under the Securities Act. Discounts,
concessions, commissions and similar selling expenses, if any, attributable
to
the sale of shares will be borne by a selling shareholder. The selling
shareholder may agree to indemnify any agent, dealer or broker-dealer that
participates in transactions involving sales of the shares if liabilities are
imposed on that person under the Securities Act.
The
selling shareholder may from time to time pledge or grant a security interest
in
some or all of the shares of common stock owned by them and, if they default
in
the performance of their secured obligations, the pledgees or secured parties
may offer and sell the shares of Class A common stock from time to time under
this prospectus after we have filed a prospectus supplement amending the list
of
selling shareholders to include the pledgee, transferee or other successors
in
interest as selling shareholders under this prospectus.
The
selling shareholder also may transfer the shares of Class A common stock in
other circumstances, in which case the transferees, pledgees or other successors
in interest will be the selling beneficial owners for purposes of this
prospectus and may sell the shares of Class A common stock from time to time
under this prospectus after we have filed a prospectus supplement amending
the
list of selling shareholders to include the pledgee, transferee or other
successors in interest as selling stockholders under this
prospectus.
The
selling shareholder and any broker-dealers or agents that are involved in
selling the shares of Class A common stock may be deemed to be “underwriters”
within the meaning of the Securities Act in connection with such sales. In
such
event, any commissions received by such broker-dealers or agents and any profit
on the resale of the shares of common stock purchased by them may be deemed
to
be underwriting commissions or discounts under the Securities Act.
The
selling shareholder has advised us that it has not entered into any agreements,
understandings or arrangements with any underwriters or broker-dealers regarding
the sale of its shares of Class A common stock, nor is there an underwriter
or
coordinating broker acting in connection with a proposed sale of shares of
Class
A common stock by the selling shareholder. If we are notified by the selling
shareholder that any material arrangement has been entered into with a
broker-dealer for the sale of shares of Class A common stock, we will
file a supplement to this prospectus if required. If the selling
shareholder uses this prospectus for any sale of the shares of Class A common
stock, it will be subject to the prospectus delivery requirements of the
Securities Act.
The
anti-manipulation rules of Regulation M under the Securities Exchange
Act of 1934 may apply to sales of our Class A common stock and activities of
the
selling shareholder.
Unless
otherwise indicated in this prospectus, Hodgson Russ LLP, Buffalo, New York
will
provide us with an opinion regarding the validity of the Class A common
stock offered hereby. John Drenning, our Corporate Secretary, is a partner
in
Hodgson Russ LLP. He and other attorneys in that firm beneficially own an
aggregate of approximately 10,500 shares of Class A common stock.
The
consolidated financial statements of Moog Inc. appearing in Moog Inc.’s Annual
Report (Form 10-K) for the year ended September 24, 2005 (including
the financial statement schedule appearing therein), and Moog Inc. management’s
assessment of the effectiveness of internal control over financial reporting
as
of September 24, 2005 included therein (which did not include an evaluation
of the internal control over financial reporting of the Power and Data
Technologies Group of the Kaydon Corporation and FCS Control Systems), have
been
audited by Ernst & Young LLP, independent registered public accounting
firm, as set forth in its reports thereon, which as to the report on internal
control over financial reporting contains an explanatory paragraph describing
the above referenced exclusion of the Power and Data Technologies Group of
the
Kaydon Corporation and FCS Control Systems from the scope of management’s
assessment and such firm’s audit of internal control over financial reporting,
included therein, and incorporated herein by reference. Such financial
statements and management’s assessment have been incorporated in this prospectus
by reference in reliance upon such reports given on the authority of
Ernst & Young as experts in accounting and auditing.
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item
14. Other Expenses of Issuance and Distribution
The
following table sets forth our estimates (other than the SEC registration fee)
of the expenses in connection with the issuance and distribution of the
securities being registered, other than underwriting discounts and
commissions.
Item
|
|
Amount
|
|
|
|
|
|
SEC
registration fee
|
|
$
|
1,788
|
|
Legal
fees and expenses
|
|
|
5,000
|
|
Accounting
fees and expenses
|
|
|
10,000
|
|
Miscellaneous
fees and expenses
|
|
|
3,212
|
|
Total
|
|
$
|
20,000
|
|
Item
15. Indemnification of Directors and Officers.
Sections 722
through 726 of the New York Business Corporation Law, or BCL, grant New York
corporations broad powers to indemnify their present and former directors and
officers and those of affiliated corporations against expenses (including
attorneys’ fees), judgments, fines and amounts paid in settlement actually and
reasonably incurred in connection with threatened, pending or completed actions,
suits or proceedings to which they are parties or are threatened to be made
parties by reason of being or having been such directors or officers, subject
to
specified conditions and exclusions; give a director or officer who successfully
defends an action the right to be so indemnified; and permit a corporation
to
buy directors’ and officers’ liability insurance. Such indemnification is not
exclusive of any other rights to which those indemnified may be entitled under
any by-laws, agreement, vote of shareholders or otherwise.
Section 402(b)
of the BCL permits a New York corporation to include in its certificate of
incorporation a provision eliminating the potential monetary liability of a
director to the corporation or its stockholders for breach of fiduciary duty
as
a director, provided that such provision shall not eliminate the liability
of a
director (i) for any breach of the director’s duty of loyalty to the
corporation or its stockholders, (ii) for acts or omissions not in good
faith or which involve intentional misconduct or a knowing violation of law,
(iii) for improper payment of dividends, or (iv) for any transaction
from which the director receives an improper personal benefit. The Registrant’s
Restated Certificate of Incorporation includes the provisions permitted by
Section 402(b) of the BCL.
The
Registrant’s By-Laws provide that it shall indemnify such directors and officers
against expenses, judgments, fines or amounts paid in settlement in connection
with any action, suit or proceeding, or threat thereof, to the maximum extent
permitted by applicable law.
Item
16. Exhibits
Exhibit
No.
|
|
Exhibit
|
|
|
|
3.1
|
|
Restated
Certificate of Incorporation of the Registrant, as amended (incorporated
by reference to Exhibit 3.1 to the Company’s Registration Statement
No. 333-113698).
|
|
|
|
3.2
|
|
Amended
By-Laws of the Registrant (incorporated by reference to Exhibit B to
the Company’s proxy statement filed under Schedule 14A on December 2,
2003).
|
|
|
|
5.1
|
|
Opinion
of Hodgson Russ LLP.
|
|
|
|
23.1
|
|
Consent
of Hodgson Russ LLP (contained in Exhibit 5.1 to this registration
statement).
|
|
|
|
23.2
|
|
Consent
of Ernst & Young LLP
|
|
|
|
24.1
|
|
Power
of Attorney (contained in Part II of this registration
statement).
|
Item
17. Undertakings
The
undersigned Registrant hereby undertakes:
(1)
To
file,
during any period in which offers or sales are being made, a post-effective
amendment to this Registration Statement:
(i)
To
include any prospectus required by Section 10(a)(3) of the Securities
Act of 1933;
(ii)
To
reflect in the prospectus any facts or events arising after the effective date
of the registration statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change
in the information set forth in the registration statement. Notwithstanding
the
foregoing, any increase or any decrease in volume of securities offered (if
the
total dollar value of securities offered would not exceed that which was
registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the
Commission pursuant to Rule 424(b) if, in the aggregate, the changes
in volume and price represent no more than a 20% change in the maximum aggregate
offering price set forth in the “Calculation of Registration Fee” table in the
effective registration statement; and
(iii)
To
include any material information with respect to the plan of distribution not
previously disclosed in the registration statement or any material change to
such information in the registration statement;
provided,
however,
that
paragraphs (1)(i), (1)(ii) and (1)(iii) do not apply if the
information required to be included in a post-effective amendment by those
paragraphs is contained in reports filed with or furnished to the Commission
by
the Registrant pursuant to Section 13 or Section 15(d) of the
Securities Exchange Act of 1934 that are incorporated by reference in the
registration statement, or is contained in a form of prospectus filed pursuant
to Rule 424(b) that is part of the registration
statement.
(2)
That,
for
the purpose of determining any liability under the Securities Act of 1933,
each
such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona
fide
offering
thereof.
(3)
To
remove
from registration by means of a post-effective amendment any of the securities
being registered which remain unsold at the termination of the
offering.
(4)
That,
for
the purpose of determining liability under the Securities Act of 1933 to any
purchaser:
(i)
Each
prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be
deemed to be part of the registration statement as of the date the filed
prospectus was deemed part of and included in the registration statement;
and
(ii)
Each
prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or
(b)(7) as part of a registration statement in reliance on Rule 430B
relating to an offering made pursuant to Rule 415(a)(l)(i), (vii) or
(x) for the purpose of providing the information required by
Section 10(a) of the Securities Act of 1933 shall be deemed to be part
of and included in the registration statement as of the earlier of the date
such
form of prospectus is first used after effectiveness or the date of the first
contract of sale of securities in the offering described in the prospectus.
As
provided in Rule 430B, for liability purposes of the issuer and any person
that is at that date an underwriter, such date shall be deemed to be a new
effective date of the registration statement relating to the securities in
the
registration statement to which the prospectus relates, and the offering of
such
securities at that time shall be deemed to be the initial bona
fide
offering
thereof. Provided,
however,
that no
statement made in a registration statement or prospectus that is part of the
registration statement or made in a document incorporated or deemed incorporated
by reference into the registration statement or prospectus that is part of
the
registration statement will, as to a purchaser with a time of contract of sale
prior to such effective date, supersede or modify any statement that was made
in
the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such effective
date.
(5)
That,
for
purposes of determining any liability under the Securities Act of 1933, each
filing of the Registrant’s annual report pursuant to Section 13(a) or
15(d) of the Securities Exchange Act of 1934 (and, where applicable, each
filing of an employee benefit plan’s annual report pursuant to
Section 15(d) of the Securities Exchange Act of 1934) that is
incorporated by reference in the registration statement shall be deemed to
be a
new registration statement relating to the securities offered therein, and
the
offering of such securities at that time shall be deemed to be the initial
bona
fide
offering
thereof.
(6)
Insofar
as indemnification for liabilities arising under the Securities Act of 1933
may
be permitted to directors, officers and controlling persons of the Registrant
pursuant to the foregoing provisions, or otherwise, the Registrant has been
advised that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Securities Act
of
1933 and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by a Registrant
of expenses incurred or paid by a director, officer or controlling person of
a
Registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with
the
securities being registered, that Registrant will, unless in the opinion of
its
counsel the matter has been settled by controlling precedent, submit to a court
of appropriate jurisdiction the question whether such indemnification by it
against public policy as expressed in the Securities Act of 1933 and will be
governed by the final adjudication of such issue.
Pursuant
to the requirements of the Securities Act of 1933, the Registrant certifies
that
it has reasonable grounds to believe that it meets all of the requirements
for
filing on Form S-3 and has duly caused this Registration Statement to be
signed on its behalf by the undersigned, thereunto duly authorized, in East
Aurora, New York on November 3, 2006.
|
|
|
|
MOOG
INC.
|
|
|
|
|
By: |
/s/
Robert T. Brady
|
|
Chairman
of the Board, President
|
|
and
Chief Executive Officer
|
POWER
OF ATTORNEY
We,
the
undersigned officers and directors of Moog Inc., hereby severally constitute
and
appoint Robert T. Brady and Robert R. Banta and each of them singly, our
true and lawful attorney and agent with full power and authority to sign for
us
and in our names in the capacities indicated below, the registration statement
on Form S-3 of Moog Inc. and any and all amendments or supplements, whether
pre-effective or post-effective, to said registration statement and generally
to
do all such things in our names and on our behalf in our capacities as officers
and directors to enable Moog Inc. to comply with the provisions of the
Securities Act of 1933, as amended, and all requirements of the Securities
and
Exchange Commission, hereby ratifying and confirming our signature as then
may
be signed by our said attorneys or any of them, to said registration statement
and any and all amendments thereto.
Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement
on Form S-3 has been signed below by the following persons in the
capacities and on the dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/
Robert T. Brady
Robert
T. Brady
|
|
Chairman
of the Board, President and Chief Executive Officer (Principal Executive
Officer) and Director
|
|
November
3, 2006
|
|
/s/
Robert R. Banta
Robert
R. Banta
|
|
Executive
Vice President, Chief Financial Officer (Principal Financial Officer)
and
Director
|
|
November
3, 2006
|
|
/s/
Donald R. Fishback
Donald
R. Fishback
|
|
Controller
(Principal Accounting Officer)
|
|
November
3, 2006
|
|
/s/
Richard A. Aubrecht
Richard
A. Aubrecht
|
|
Director
|
|
November
3, 2006
|
/s/
Raymond W. Boushie
Raymond
W. Boushie
|
|
Director
|
|
November
3, 2006
|
|
|
|
|
|
James
L. Gray
|
|
Director
|
|
|
|
|
|
|
|
/s/
Joe C. Green
Joe
C. Green
|
|
Director
|
|
November
3, 2006
|
|
|
|
|
|
Kraig
H. Kayser
|
|
Director
|
|
|
|
|
|
|
|
/s/ Brian J. Lipke
Brian
J. Lipke
|
|
Director
|
|
November 3, 2006 |
|
|
|
|
|
/s/
Robert H. Maskrey
Robert
H. Maskrey
|
|
Director
|
|
November
3, 2006
|
|
|
|
|
|
Albert
F. Myers
|
|
Director
|
|
|
|
|
|
|
|
/s/ John Hendrickson
John
Hendrickson
|
|
Director
|
|
November 3, 2006 |
|
|
|
|
|
EXHIBIT
INDEX
Exhibit
No.
|
|
Exhibit
|
|
|
|
3.1
|
|
Restated
Certificate of Incorporation of the Registrant, as amended (incorporated
by reference to Exhibit 3.1 to the Company’s Registration Statement
No. 333-113698).
|
|
|
|
3.2
|
|
Amended
By-Laws of the Registrant (incorporated by reference to Exhibit B to
the Company’s proxy statement filed under Schedule 14A on December 2,
2003).
|
|
|
|
5.1
|
|
Opinion
of Hodgson Russ LLP.
|
|
|
|
23.1
|
|
Consent
of Hodgson Russ LLP (contained in Exhibit 5.1 to this registration
statement).
|
|
|
|
23.2
|
|
Consent
of Ernst & Young LLP
|
|
|
|
24.1
|
|
Power
of Attorney (contained in Part II of this registration
statement).
|